uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS

uniQure (NASDAQ:QURE) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21, Zacks reports. The firm had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%.

uniQure Price Performance

Shares of QURE stock opened at $7.43 on Friday. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $11.35. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36. The firm has a market capitalization of $361.84 million, a price-to-earnings ratio of -1.25 and a beta of 0.90. The stock’s 50-day simple moving average is $5.73 and its 200-day simple moving average is $5.80.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 target price on shares of uniQure in a report on Wednesday. Raymond James restated an “outperform” rating and set a $20.00 price objective on shares of uniQure in a research note on Thursday, October 10th. StockNews.com upgraded uniQure to a “sell” rating in a research note on Thursday, October 17th. Royal Bank of Canada reduced their target price on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, The Goldman Sachs Group lowered their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.00.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.